Sp465
PANEL DISCUSSION
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis. This session will review the efficacy, safety and practical applications for use of these agents in the management of ulcerative colitis and examine their role in Crohn’s disease. . It will also examine the current role of non-targeted small molecules (thiopurines and methotrexate), diet, and microbiome-directed therapies in the treatment of IBD.
In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis. This session will review the efficacy, safety and practical applications for use of these agents in the management of ulcerative colitis and examine their role in Crohn’s disease. . It will also examine the current role of non-targeted small molecules (thiopurines and methotrexate), diet, and microbiome-directed therapies in the treatment of IBD.
Presenters
Mayo Clinic
University of California san francisco
Mayo Foundation for Medical Education and Research
Massachusetts General Hospital
Tracks
Related Products
GUT MICROBIAL METABOLISM OF 5-ASA IS PROSPECTIVELY ASSOCIATED WITH TREATMENT FAILURE
The microbiome plays a central role in intestinal inflammation in IBD. It is influenced by environmental factors included diet…
INFLAMMATORY BOWEL DISEASE AND THE RISK OF ANAL DYSPLASIA AND CANCER AMONG MEN WHO HAVE SEX WITH MEN
BACKGROUND: The impact of pregnancy on vedolizumab (VDZ) and ustekinumab (UST) pharmacokinetics is not well defined. Similarly, the time to infant clearance and outcomes following in-utero exposure require elucidation…
THE SULFUR MICROBIAL DIET AND RISK OF INFLAMMATORY BOWEL DISEASE
BACKGROUND The gut microbiome is central to Crohn’s disease (CD) pathogenesis but the relative contribution of different environmental factors to disease compositional variation is unknown…
